SELLAS Life Sciences Group, Inc.
NASDAQSLS utilization hits 90.54%, highest in 52-week period as borrow scarcity persists despite recent availability relief.
SELLAS Life Sciences Group reported its Q2 results on August 12 with one of the most heavily contested short positions in small-cap biotech still intact — and the data since the print shows bears have not…
SELLAS Life Sciences Group heads into its August 12 earnings report as one of the most heavily shorted small-cap biotechs in the market, with the lending pool telling a story of sustained bear conviction — even as…
Snapshot as of 20 Aug 2026
SELLAS Life Sciences enters the second week of July in a different borrow regime than it occupied ten days ago — the acute squeeze pressure has partially unwound, but the underlying short conviction has not. The borrow…
SELLAS Life Sciences has crossed into territory where the lending market offers almost nothing to new short sellers. Availability has collapsed to 0.04% — effectively zero. Every share in the lending pool is now out on…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SLS — free to start on ORTEX.
Sign up for free →Open SLS on ORTEX